Probiotic-Derived Exosome Development

Q: Which probiotic species do you work with?

Our standard platform covers lactic acid bacteria (Lactobacillus, Lactiplantibacillus, Limosilactobacillus, Lacticaseibacillus, Levilactobacillus) and bifidobacteria (Bifidobacterium spp.). We also work with propionibacteria and bacilli with probiotic status. For niche applications, custom species can be evaluated upon request.

Q: What is the minimum order for a pilot production batch?

Pilot-scale pEV production typically yields 1013–1015 particles per batch at 10–50 L fermentation scale. Minimum pilot batch quantities are project-dependent but typically sufficient for preclinical studies and initial formulation development.

Inquiry

OverviewServicesSamplesAdvantagesApplicationsCase StudyFAQs

Overview

At Creative BioMart Microbe, we provide end-to-end probiotic-derived extracellular vesicle (pEV) development services spanning the complete value chain from strain identification to product-ready formulation. Our platform integrates probiotic strain screening and taxonomic characterization, fermentation process optimization for high-yield vesicle production, specialized isolation and purification protocols for Gram-positive cytoplasmic membrane vesicles (CMVs), comprehensive functional validation for gut health, immunomodulation, and skin barrier applications, and scalable product formulation for functional foods, nutraceuticals, and cosmetic active ingredients.

Unlike generic exosome CROs that apply mammalian or Gram-negative bacterial protocols to probiotic systems, we have developed dedicated workflows for the unique cell wall architecture, membrane composition, and biogenesis mechanisms of lactic acid bacteria and bifidobacteria. From wild-type strain isolation to product-grade pEV batches with validated bioactivity, clients receive a complete development package that includes characterized production strains, optimized fermentation protocols, purified pEV preparations, functional efficacy data, and formulation recommendations suitable for product registration and commercial launch. Contact us to discuss your probiotic-derived exosome development project.

Scientific schematic of integrated probiotic-derived extracellular vesicle development platform showing strain screening, fermentation optimization, isolation purification, functional validation, and product formulation modules arranged along a vertical development pipeline.
Figure 1. Schematic overview of the integrated probiotic-derived extracellular vesicle development platform, spanning probiotic strain screening, fermentation process optimization, specialized isolation and purification, functional validation, and product formulation for commercial applications.

Services

Service Workflow

Commercial end-to-end service workflow diagram for probiotic-derived exosome development showing seven stages from strain sourcing through taxonomic identification, fermentation optimization, vesicle isolation, functional profiling, formulation development, scale-up correlation, and final product delivery with full documentation.

Inquiry

Service Details

Isometric automation scene showing multiple probiotic bacterial colonies on petri dishes, with robotic arms transferring samples to analytical stations for 16S rRNA sequencing, MALDI-TOF identification, and phenotypic screening.

Probiotic Strain Screening & Taxonomic Characterization

We identify, isolate, and characterize high-pEV-yielding probiotic strains from natural sources, culture collections, or client-provided isolates. Our capabilities include taxonomic identification by 16S rRNA gene sequencing and MALDI-TOF mass spectrometry, phenotypic profiling for acid and bile tolerance, adherence capacity, and safety assessment, and pEV yield ranking across candidate strains under standardized culture conditions. Strain safety evaluation covers antibiotic resistance profiling, hemolytic activity, and biogenic amine production. Clients receive fully characterized probiotic strains with taxonomic certificates, phenotypic profiles, and pEV yield rankings that support strain selection for downstream development and regulatory dossiers.

3D equipment rendering showing a bench-top bioreactor system with process analytical technology sensors, connected to data acquisition dashboards displaying dissolved oxygen, pH, and growth curves for probiotic culture optimization.

Probiotic Fermentation Process Development

We optimize fermentation parameters to maximize pEV yield and bioactivity from lactic acid bacteria and bifidobacteria. Our capabilities include media composition screening, bioreactor process parameter optimization, growth phase harvesting window identification, and stress-induced vesicle enhancement protocols (pH shift, temperature modulation, nutrient limitation). Process analytical technology enables real-time monitoring of biomass, pH, dissolved oxygen, and metabolic byproducts. Scale-up correlation analysis links laboratory shake flask performance to bench-top bioreactor and pilot-scale outcomes. Clients receive optimized fermentation protocols with defined media recipes, process parameters, harvest criteria, and scale-up guidelines that support manufacturing technology transfer.

Process flow illustration showing sequential stages of probiotic CMV isolation from dense Gram-positive cell walls, including cell wall disruption, differential centrifugation, membrane vesicle enrichment, and final purification to high-purity pEV product.

Probiotic EV Isolation & Purification

We apply specialized isolation protocols designed for the thick peptidoglycan cell walls and cytoplasmic membrane vesicle biogenesis of Gram-positive probiotics. Our capabilities include mechanical and enzymatic cell wall disruption (e.g., lysozyme, mutanolysin), differential centrifugation for debris removal, membrane vesicle enrichment by ultrafiltration and density gradient separation, and contaminant removal protocols for lipoteichoic acid and residual cellular components. Purification yields are monitored by nanoparticle tracking analysis, dynamic light scattering, and protein-to-particle ratio optimization. Clients receive purified pEV preparations with defined purity grades (research, preclinical, or product-grade) and full physicochemical characterization reports.

Macroscopic biological scene showing parallel functional assay contexts for probiotic EVs: intestinal epithelial barrier with tight junctions, immune cells with cytokine induction, and skin fibroblasts with collagen production, all responding to pEV treatment.

Probiotic EV Functional Validation

We validate the bioactivity of pEVs across the therapeutic modalities most relevant to probiotic applications. Our capabilities include intestinal barrier integrity assessment using Caco-2 monolayer models, immunomodulatory profiling by macrophage polarization and cytokine induction assays, anti-inflammatory activity evaluation in LPS-stimulated immune cells, and skin barrier function testing on human dermal fibroblasts including collagen synthesis and elastase inhibition. Functional benchmarking compares pEV potency against established probiotic strains and positive controls. Clients receive comprehensive functional validation reports with dose-response data, mechanism-of-action insights, and efficacy rankings that support product positioning and marketing claims.

Abstract data visualization showing formulation optimization matrices with stability heatmaps, scale-up correlation scatter plots linking small-batch and production-scale yields, and shelf-life prediction curves for probiotic EV products.

Probiotic EV Product Formulation & Scale-Up Development

We develop stable, shelf-ready formulations for pEV integration into functional foods, dietary supplements, and cosmetic products. Our capabilities include encapsulation technology screening for gastric stability, bioavailability enhancement, and controlled release, compatibility assessment with food matrices and cosmetic bases, accelerated stability testing under product-category-specific protocols (ICH-aligned for pharmaceutical-track products, cosmetic stability guidelines for topical formulations, food shelf-life protocols for edible applications). Scale-up correlation validates that laboratory-scale pEV quality and bioactivity are maintained at production volumes. Regulatory support includes GRAS self-affirmation documentation, cosmetic ingredient safety assessments, and product specification development. Clients receive formulation prototypes, stability data packages, and regulatory-ready documentation for product commercialization.

Service Specifications & QC Standards

Instrumentation & Capability

Microbial Identification: 16S rRNA gene sequencing and MALDI-TOF mass spectrometry for taxonomic characterization.
Fermentation Systems: Bench-top bioreactors with process analytical technology for real-time parameter monitoring and optimization.
Vesicle Isolation: Mechanical disruption, enzymatic digestion, ultrafiltration, and density gradient separation systems.
Nanoparticle Analysis: Real-time particle tracking and dynamic light scattering for concentration, size, and polydispersity.
Functional Assays: Intestinal epithelial monolayer systems, immune cell culture platforms, and dermal fibroblast models.
Cytokine Profiling: Multiplex bead array and automated ELISA for inflammatory and immunomodulatory marker quantification.
Formulation Development: Encapsulation and microencapsulation systems for food-grade and cosmetic-grade delivery.

Typical Data Range

Strain screening panel: 5–20 probiotic isolates per campaign.
pEV yield range: 10⁹–10¹¹ particles/mL culture supernatant under standard conditions; optimized strains may reach 10¹² particles/mL with stress-induced enhancement (strain dependent).
Fermentation yield improvement: 2–10-fold increase after process optimization.
Purified pEV purity: >90% particle enrichment with <5% cellular debris contamination.
Barrier repair TEER recovery: 20–50% restoration in Caco-2 models.
Anti-inflammatory cytokine suppression: 30–70% reduction in TNF-α and IL-6.
Skin collagen induction: 1.5–3-fold increase in type I collagen expression.
Formulation stability at 25°C: >80% particle retention for 6 months.

Turnaround Time

Project Type	Timeline
Strain screening and identification (up to 10 strains)	3–4 weeks
Taxonomic characterization and safety profiling	2–3 weeks
Fermentation process optimization	4–6 weeks
pEV isolation and purification protocol development	3–4 weeks
Functional validation package (barrier, immune, skin)	4–6 weeks
Formulation development and stability testing	6–10 weeks
Integrated pEV product development package	16–24 weeks
Expedited timeline	+50% fee, 40% time reduction

Timeline may vary based on strain number, functional assay scope, and formulation complexity.

Deliverables

Strain screening report: Taxonomic identification, phenotypic profiles, pEV yield rankings, safety assessment.
Fermentation protocol: Optimized media composition, process parameters, harvest criteria, scale-up guidelines.
Isolation report: Purification protocol, yield data, purity metrics, physicochemical characterization.
Functional validation report: Dose-response curves, mechanism data, efficacy rankings, positive control comparisons.
Formulation package: Prototype formulations, stability data, sensory evaluation, regulatory documentation.
Integrated product dossier: Complete strain-to-product documentation for registration and commercialization.

Quality Control

Strain identity confirmation by 16S rRNA sequencing for all production strains.
Pre-purification baseline: NTA, DLS, and protein content on every batch.
Post-purification QC: Particle concentration, size distribution, purity, and lipoteichoic acid (LTA) level (Gram-positive-specific contaminant; endotoxin screening included for cross-contamination monitoring).
Functional assay controls: Context-specific positive controls (anti-inflammatory: dexamethasone; barrier repair: established probiotic strains; collagen induction: TGF-β reference), negative controls (vesicle-depleted supernatant).
Intra-assay CV ≤ 15%; inter-assay CV ≤ 20% for all quantitative endpoints.
Batch consistency: CV < 20% for yield and bioactivity across three independent batches.
Compliance checklist for minimal characterization requirements aligned with industry guidelines for extracellular vesicle studies.

Sample Requirements

Required Information	Optional Information	Not Accepted
Strain source (natural isolate, culture collection, client-provided) Probiotic species or genus of interest Target application (functional food, nutraceutical, cosmetic) Desired pEV yield or production scale Intended formulation type (liquid, powder, capsule, cream) Safety and regulatory requirements (GRAS, cosmetic ingredient)	Prior fermentation or isolation data Specific bioactivity targets (barrier repair, anti-inflammatory, skin) Reference probiotic strain for benchmarking Product shelf-life requirements Sensory or aesthetic constraints for cosmetics Regulatory submission timeline	Non-probiotic or pathogenic bacterial strains Strains with undocumented origin or safety profile Genetically modified organisms without proper documentation Contaminated or mixed cultures Strains with known antibiotic resistance transfer risk Samples shipped without cold-chain documentation

Recommended Sample Quantity by Service:

Service	Minimum	Recommended
Strain screening (per isolate)	Glycerol stock or agar stab	1 mL glycerol stock
Fermentation optimization	1 isolate	3 isolates for comparison
pEV isolation development	500 mL culture	1–2 L culture
Functional validation	200 μL purified pEV	500 μL purified pEV
Formulation development	1 mL purified pEV	2–5 mL purified pEV
Integrated development package	3 isolates + 5 mL pEV	5 isolates + 10 mL pEV

Storage & Shipping: Ship probiotic strains as glycerol stocks on dry ice with cold-chain documentation. Provide strain origin, isolation history, and any prior characterization data. For pEV samples, ship purified suspensions on dry ice in sterile PBS. Include certificate of analysis if available. For formulation projects, provide target product specifications and regulatory requirements.

Inquiry

Our Advantages

Probiotic-Specific Expertise: Our workflows are purpose-built for Gram-positive probiotic biologies, including lactic acid bacteria and bifidobacteria, with optimized protocols for their thick peptidoglycan cell walls, acid tolerance mechanisms, and CMV biogenesis that differ fundamentally from Gram-negative OMV platforms.
End-to-End Development: We offer the complete pEV development chain from wild-type strain isolation through fermentation optimization, purification, functional validation, and product formulation, eliminating the need to coordinate across multiple vendors.
Multi-Modal Functional Validation: Our validation platform spans gut barrier, immune modulation, and skin health endpoints, reflecting the three primary commercial application areas for probiotic EVs and providing comprehensive efficacy evidence.
Regulatory Pathway Support: We prepare GRAS self-affirmation dossiers, cosmetic ingredient safety assessments, and product specifications aligned with FDA, EFSA, and cosmetic regulatory frameworks for probiotic-derived ingredients.
Strain Bank & IP Protection: All client-provided strains are handled under confidentiality agreements with secure strain banking, and proprietary fermentation protocols are documented for technology transfer and intellectual property protection.

Applications

Scene-based storytelling showing a functional food product with encapsulated probiotic EVs traveling through the digestive tract and enhancing intestinal barrier integrity.

Probiotic EV Gut Health Functional Foods

Barrier-repair pEVs integrated into functional foods for digestive wellness and gut microbiome modulation.

Left-to-right narrative flow from probiotic EV production through immunomodulatory validation to encapsulated nutraceutical supplements for immune support.

Probiotic EV Immune Nutraceuticals

Anti-inflammatory and immunomodulatory pEVs formulated as dietary supplements for immune health.

Scale transition from cosmetic cream formulation down to skin fibroblast level showing collagen induction and barrier reinforcement by probiotic EV actives.

Probiotic EV Skin Barrier Cosmetics

Collagen-boosting and anti-aging pEVs as active ingredients in premium skincare formulations.

Top-to-bottom cascade from characterized probiotic strain through GMP-compliant pEV production to preclinical therapeutic candidate for inflammatory bowel disease.

Probiotic EV Therapeutic Candidate Development

Clinical-grade pEV development for therapeutic applications in inflammatory and autoimmune diseases.

Case Study

Case Study: Lactiplantibacillus plantarum (formerly Lactobacillus plantarum)-Derived Extracellular Vesicles for Skin Anti-Aging

Researchers isolated Lactiplantibacillus plantarum from the skin of women in their 20s and developed its extracellular vesicles (LpEVs) as a topical anti-aging agent. LpEVs were characterized by nanoparticle tracking analysis (NTA), revealing a mean diameter of 126.5 ± 56.4 nm and a concentration of 9.1 × 10⁹ particles/mL. In vitro studies on CCD986sk human dermal fibroblasts demonstrated that LpEVs modulated extracellular matrix (ECM) gene expression in a dose-dependent manner (0.625%–10%), upregulating type I collagen (1.6-fold at 10%), filaggrin (>2-fold at 2.5%–10%), and HAS2 protein (20–30% at 5%–10%) while downregulating matrix metalloproteinase-1 (MMP-1) and inhibiting elastase activity (40% at 10%). UVA-irradiated senescent fibroblast models were used to validate anti-aging efficacy.

A 4-week randomized clinical trial with 16 Korean women (mean age in 50s) compared LpEVs formulation against a mannitol 5% placebo. LpEVs treatment significantly improved periorbital wrinkles (−15.89%), skin elasticity (+27.07%), hydration (+21.40%), and dermal density (+39.30% vs. placebo +15.19%). Marked reductions in pigmentation (−8.7%) were also observed. This study demonstrates how probiotic-derived extracellular vesicles can be developed from strain isolation through in vitro validation to clinical proof-of-concept, establishing a development paradigm for pEV-based cosmetic and dermatological products.

Clinical trial evaluation of LpEVs on wrinkle formation showing eye-wrinkle improvement assessments, epidermis elasticity improvement results, and Antera 3D images from clinical trials.
Figure 2. Evaluation of the effects of LpEVs on wrinkle formation. (Jo, et al. 2022)

FAQs

Q: Which probiotic species do you work with?

A: Our standard platform covers lactic acid bacteria (Lactobacillus, Lactiplantibacillus, Limosilactobacillus, Lacticaseibacillus, Levilactobacillus) and bifidobacteria (Bifidobacterium spp.). We also work with propionibacteria and bacilli with probiotic status. For niche applications, custom species can be evaluated upon request.

Q: What is the difference between probiotic EVs and bacterial OMVs?

A: Probiotic extracellular vesicles (pEVs) from Gram-positive bacteria are cytoplasmic membrane vesicles (CMVs) that bud from the cytoplasmic membrane through the thick peptidoglycan cell wall. CMV biogenesis involves cell wall remodeling by autolysins or phage-encoded endolysins that locally degrade peptidoglycan, enabling cytoplasmic membrane protrusion and vesicle release through a process known as bubbling cell death. Bacterial outer membrane vesicles (OMVs) from Gram-negative bacteria bud from the outer membrane through a blebbing mechanism. pEVs lack lipopolysaccharide (LPS) and typically have lower inherent immunogenicity, making them particularly suitable for food, cosmetic, and therapeutic applications requiring high safety margins.

Q: Can you develop pEVs from client-provided probiotic strains?

A: Yes. We accept client-provided probiotic isolates, commercial probiotic cultures, and strains from public repositories (ATCC, DSMZ). All client strains are handled under confidentiality agreements. We can also source strains from repositories on your behalf.

Q: How do you ensure probiotic strain safety?

A: Every production strain undergoes comprehensive safety profiling including antibiotic resistance screening, hemolytic activity testing, biogenic amine production assessment, and virulence factor screening. Only strains passing all safety criteria are advanced to fermentation and product development.

Q: What formulation types can you develop?

A: We develop liquid suspensions, lyophilized powders, microencapsulated beads, and oil-in-water emulsions for food and nutraceutical applications. For cosmetics, we formulate serums, creams, lotions, and masks compatible with pEV stability requirements.

Q: Do pEVs retain bioactivity after encapsulation or formulation?

A: Bioactivity retention depends on the encapsulation method and formulation matrix. Our encapsulation screening identifies conditions that maintain >80% functional activity after processing. Stability testing confirms bioactivity retention over the declared shelf life.

Q: Can you support GRAS or cosmetic ingredient registration?

A: Yes. We provide GRAS self-affirmation documentation packages including strain characterization, safety data, consumption exposure assessments, and expert panel review support. For cosmetic ingredients, we prepare safety dossiers aligned with EU Cosmetic Regulation and FDA cosmetic guidance.

Q: What is the minimum order for a pilot production batch?

A: Pilot-scale pEV production typically yields 10¹³–10¹⁵ particles per batch at 10–50 L fermentation scale. Minimum pilot batch quantities are project-dependent but typically sufficient for preclinical studies and initial formulation development.

References:

Jo, C.S., et al. (2022). The Effect of Lactobacillus plantarum Extracellular Vesicles from Korean Women in Their 20s on Skin Aging. Current Issues in Molecular Biology, 44(2), 526–540.

Services

Inquiry